BioCentury | Nov 21, 2020

Mei readies Antengene to take its next steps to becoming a global biotech

Fresh off its $360 million IPO on the Hong Kong stock exchange, Shanghai’s Antengene is looking to take the next step in its evolution by building out its pipeline and launching its first drug....
BioCentury | Nov 7, 2020
Emerging Company Profile

Vaxxinity: supplanting mAbs with vaccines for chronic disease

Vaxxinity aims to disrupt the biologics market with a vaccine platform that replaces mAbs for chronic disease by inducing patients’ immune systems to manufacture therapeutic antibodies in vivo. But...
BioCentury | Oct 1, 2020
Product Development

Sept. 30 Quick Takes: $234M for NIH’s RADx-UP; plus CureVac, Allena, Covaxx

NIH in push to improve COVID-19 testing for underserved populationsThe National Institutes of Health has awarded about $234 million to improve COVID-19 testing for underserved and vulnerable populations via the RADx Underserved Populations program. A...
BioCentury | Jul 17, 2020

Bischofberger revisits Gilead castoff to pad Kronos’ pipeline of transcription modulators

New biomarker data for a clinical cancer therapy discontinued by Gilead prompted Kronos President and CEO Norbert Bischofberger to close a deal with his old company to bring the IP in-house to Kronos. The acquisition...
BioCentury | Apr 14, 2020

Expanded deal with Kyowa could give MEI cash through drug approval

Building on a 2018 deal in Japan, MEI Pharma granted Kyowa Kirin ex-U.S. rights to its PI3Kδ inhibitor ME-401 in an expanded partnership that could shore up the San Diego-based biotech’s balance sheet through a...
BioCentury | Dec 19, 2019

Inhibiting the EIF4G1-EIF4E interaction to treat autism

DISEASE CATEGORY: Neurology INDICATION: Autism Disrupting the EIF4G1-EIF4E interaction could treat autism, a disorder characterized by social deficits and associated with increased dendritic spine densities and mutations in the E3 ligase complex component CUL3. In...
BioCentury | Jun 26, 2019
Clinical News

June 25 Clinical Quick Takes: Minerva meets in insomnia; plus Aldeyra, Genkyotex and more

Minerva rises with insomnia data Seltorexant (MIN-202) from Minerva Neurosciences Inc. (NASDAQ:NERV) met the primary endpoint of reducing Latency to Persistent Sleep (LPS) at night 1 vs. placebo (p≤0.001) in a Phase IIb trial to...
BioCentury | Apr 22, 2019
Distillery Techniques

Bacterial recA-based CRISPR system for high-efficiency gene editing

TECHNIQUES CATEGORY: Drug platforms TECHNOLOGY: Gene therapy A CRISPR-based gene editing system utilizing bacterial recA could correct disease-causing point mutations with greater efficiency than standard CRISPR-based systems. The system consists of a corrected single-strand DNA...
BioCentury | Mar 9, 2019
Clinical News

AMAG sinks after Makena misses confirmatory trial

AMAG lost $2.43 (18%) to $11.29 on Friday after reporting that intramuscular Makena hydroxyprogesterone caproate -- the drug that created a political firestorm over its pricing eight years ago -- missed the co-primary endpoints in...
BioCentury | Nov 26, 2018
Distillery Therapeutics


INDICATION: Breast cancer Cell culture and zebrafish studies identified a tanshinone-based compound that could help treat metastatic triple-negative breast cancer (TNBC). Chemical synthesis and testing in a human TNBC cell line of imidazole analogs of...
Items per page:
1 - 10 of 103